No Data
No Data
Invex Therapeutics (ASX:IXC) Shareholders Have Endured a 52% Loss From Investing in the Stock Three Years Ago
Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return
Invex Therapeutics Ltd (ASX:IXC) said in an Australian bourse filing on Wednesday that the Australian Taxation Office has published a class ruling relating to the company's AU$0.14 per share return of
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses
Invex Therapeutics (ASX:IXC) narrowed loss after tax attributable to members for the six months ended Dec. 31, 2023, to AU$2.1 million, or AU$0.0281 per share, from AU$3.8 million, or AU$0.0512 per sh
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal
Biopharmaceutical company Invex Therapeutics (ASX:IXC) and Peptron (KOSDAQ:087010) mutually terminated their collaboration and manufacturing agreement, according to a Friday release. Under the termina
AU Morning Wrap: ASX Opens Lower; Bid Targets Adbri, Link Group Soar 30%
Stocks to watch: Adbri, Link Group, Stockland.
Invex Therapeutics to Secure European Patent Grant for Neurological Medication
Invex Therapeutics (ASX:IXC) received notice from the European Patent Office of its decision to grant a patent to the biopharmaceutical firm's Presendin medication for the treatment of certain neurolo
No Data